Dihydrolipoic acid inhibits skin tumor promotion through anti-inflammation and anti-oxidation

Yuan Soon Ho, Ching Shu Lai, Hsin I. Liu, Sheng Yow Ho, Chein Tai, Min Hsiung Pan, Ying Jan Wang

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

α-Lipoic acid (LA) has been intensely investigated as a therapeutic agent for several diseases, including hepatic disorder and diabetic polyneuropathy. However, the effects of LA or its reduced form, dihydrolipoic acid (DHLA), on cancer chemoprevention has never been reported. In the present study, we examined the effects of DHLA/LA on the production of nitric oxide (NO) by inducible NO synthase (iNOS) and the formation of prostaglandin E2 (PGE2) by cyclooxygenase-2 (COX-2), two important mediators associated with inflammation. DHLA/LA significantly inhibited lipopolysaccharide (LPS)-induced NO and PGE2 formation in RAW 264.7 cells. Meanwhile, treatment with DHLA/LA suppressed the expression of iNOS protein but, unexpectedly, did not affect or increase the expression of COX-2 protein. The in vivo anti-inflammatory and antitumor-promoting activities were evaluated by a topical 12-O-tetradecanoylphorbol 13-acetate (TPA) application to mouse skin with measurement of edema formation, epidermal thickness and hydrogen peroxide production. DHLA significantly inhibited the priming and activation stages of skin inflammation induced by a double TPA application, by decreasing the inflammatory parameters. Furthermore, DHLA inhibited DMBA (0.3 μmol)/TPA (2.0 nmol)-induced skin tumor formation by reducing the tumor incidence and tumor multiplicity. When applied topically onto the shaven backs of mice prior to TPA, DHLA markedly inhibited the expression of iNOS protein. DHLA also strongly and directly inhibited COX-2 activity. These results suggest that DHLA can be a possible chemopreventive agent in inflammation-associated tumorigenesis.

Original languageEnglish
Pages (from-to)1786-1795
Number of pages10
JournalBiochemical Pharmacology
Volume73
Issue number11
DOIs
Publication statusPublished - Jun 1 2007

Fingerprint

Tumors
Skin
Thioctic Acid
Inflammation
Oxidation
Tetradecanoylphorbol Acetate
Neoplasms
Acetates
Cyclooxygenase 2
Dinoprostone
Nitric Oxide Synthase
Nitric Oxide
dihydrolipoic acid
9,10-Dimethyl-1,2-benzanthracene
Proteins
Diabetic Neuropathies
Chemoprevention
Nitric Oxide Synthase Type II
Prostaglandin-Endoperoxide Synthases
Hydrogen Peroxide

Keywords

  • α-Lipoic acid (LA)
  • Cancer chemoprevention
  • Dihydrolipoic acid (DHLA)
  • Inflammation
  • Oxidative stress
  • Tumor promotion

ASJC Scopus subject areas

  • Pharmacology

Cite this

Dihydrolipoic acid inhibits skin tumor promotion through anti-inflammation and anti-oxidation. / Ho, Yuan Soon; Lai, Ching Shu; Liu, Hsin I.; Ho, Sheng Yow; Tai, Chein; Pan, Min Hsiung; Wang, Ying Jan.

In: Biochemical Pharmacology, Vol. 73, No. 11, 01.06.2007, p. 1786-1795.

Research output: Contribution to journalArticle

Ho, Yuan Soon ; Lai, Ching Shu ; Liu, Hsin I. ; Ho, Sheng Yow ; Tai, Chein ; Pan, Min Hsiung ; Wang, Ying Jan. / Dihydrolipoic acid inhibits skin tumor promotion through anti-inflammation and anti-oxidation. In: Biochemical Pharmacology. 2007 ; Vol. 73, No. 11. pp. 1786-1795.
@article{6581448bbefc4396b1df83ebf969fb9f,
title = "Dihydrolipoic acid inhibits skin tumor promotion through anti-inflammation and anti-oxidation",
abstract = "α-Lipoic acid (LA) has been intensely investigated as a therapeutic agent for several diseases, including hepatic disorder and diabetic polyneuropathy. However, the effects of LA or its reduced form, dihydrolipoic acid (DHLA), on cancer chemoprevention has never been reported. In the present study, we examined the effects of DHLA/LA on the production of nitric oxide (NO) by inducible NO synthase (iNOS) and the formation of prostaglandin E2 (PGE2) by cyclooxygenase-2 (COX-2), two important mediators associated with inflammation. DHLA/LA significantly inhibited lipopolysaccharide (LPS)-induced NO and PGE2 formation in RAW 264.7 cells. Meanwhile, treatment with DHLA/LA suppressed the expression of iNOS protein but, unexpectedly, did not affect or increase the expression of COX-2 protein. The in vivo anti-inflammatory and antitumor-promoting activities were evaluated by a topical 12-O-tetradecanoylphorbol 13-acetate (TPA) application to mouse skin with measurement of edema formation, epidermal thickness and hydrogen peroxide production. DHLA significantly inhibited the priming and activation stages of skin inflammation induced by a double TPA application, by decreasing the inflammatory parameters. Furthermore, DHLA inhibited DMBA (0.3 μmol)/TPA (2.0 nmol)-induced skin tumor formation by reducing the tumor incidence and tumor multiplicity. When applied topically onto the shaven backs of mice prior to TPA, DHLA markedly inhibited the expression of iNOS protein. DHLA also strongly and directly inhibited COX-2 activity. These results suggest that DHLA can be a possible chemopreventive agent in inflammation-associated tumorigenesis.",
keywords = "α-Lipoic acid (LA), Cancer chemoprevention, Dihydrolipoic acid (DHLA), Inflammation, Oxidative stress, Tumor promotion",
author = "Ho, {Yuan Soon} and Lai, {Ching Shu} and Liu, {Hsin I.} and Ho, {Sheng Yow} and Chein Tai and Pan, {Min Hsiung} and Wang, {Ying Jan}",
year = "2007",
month = "6",
day = "1",
doi = "10.1016/j.bcp.2006.12.006",
language = "English",
volume = "73",
pages = "1786--1795",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Dihydrolipoic acid inhibits skin tumor promotion through anti-inflammation and anti-oxidation

AU - Ho, Yuan Soon

AU - Lai, Ching Shu

AU - Liu, Hsin I.

AU - Ho, Sheng Yow

AU - Tai, Chein

AU - Pan, Min Hsiung

AU - Wang, Ying Jan

PY - 2007/6/1

Y1 - 2007/6/1

N2 - α-Lipoic acid (LA) has been intensely investigated as a therapeutic agent for several diseases, including hepatic disorder and diabetic polyneuropathy. However, the effects of LA or its reduced form, dihydrolipoic acid (DHLA), on cancer chemoprevention has never been reported. In the present study, we examined the effects of DHLA/LA on the production of nitric oxide (NO) by inducible NO synthase (iNOS) and the formation of prostaglandin E2 (PGE2) by cyclooxygenase-2 (COX-2), two important mediators associated with inflammation. DHLA/LA significantly inhibited lipopolysaccharide (LPS)-induced NO and PGE2 formation in RAW 264.7 cells. Meanwhile, treatment with DHLA/LA suppressed the expression of iNOS protein but, unexpectedly, did not affect or increase the expression of COX-2 protein. The in vivo anti-inflammatory and antitumor-promoting activities were evaluated by a topical 12-O-tetradecanoylphorbol 13-acetate (TPA) application to mouse skin with measurement of edema formation, epidermal thickness and hydrogen peroxide production. DHLA significantly inhibited the priming and activation stages of skin inflammation induced by a double TPA application, by decreasing the inflammatory parameters. Furthermore, DHLA inhibited DMBA (0.3 μmol)/TPA (2.0 nmol)-induced skin tumor formation by reducing the tumor incidence and tumor multiplicity. When applied topically onto the shaven backs of mice prior to TPA, DHLA markedly inhibited the expression of iNOS protein. DHLA also strongly and directly inhibited COX-2 activity. These results suggest that DHLA can be a possible chemopreventive agent in inflammation-associated tumorigenesis.

AB - α-Lipoic acid (LA) has been intensely investigated as a therapeutic agent for several diseases, including hepatic disorder and diabetic polyneuropathy. However, the effects of LA or its reduced form, dihydrolipoic acid (DHLA), on cancer chemoprevention has never been reported. In the present study, we examined the effects of DHLA/LA on the production of nitric oxide (NO) by inducible NO synthase (iNOS) and the formation of prostaglandin E2 (PGE2) by cyclooxygenase-2 (COX-2), two important mediators associated with inflammation. DHLA/LA significantly inhibited lipopolysaccharide (LPS)-induced NO and PGE2 formation in RAW 264.7 cells. Meanwhile, treatment with DHLA/LA suppressed the expression of iNOS protein but, unexpectedly, did not affect or increase the expression of COX-2 protein. The in vivo anti-inflammatory and antitumor-promoting activities were evaluated by a topical 12-O-tetradecanoylphorbol 13-acetate (TPA) application to mouse skin with measurement of edema formation, epidermal thickness and hydrogen peroxide production. DHLA significantly inhibited the priming and activation stages of skin inflammation induced by a double TPA application, by decreasing the inflammatory parameters. Furthermore, DHLA inhibited DMBA (0.3 μmol)/TPA (2.0 nmol)-induced skin tumor formation by reducing the tumor incidence and tumor multiplicity. When applied topically onto the shaven backs of mice prior to TPA, DHLA markedly inhibited the expression of iNOS protein. DHLA also strongly and directly inhibited COX-2 activity. These results suggest that DHLA can be a possible chemopreventive agent in inflammation-associated tumorigenesis.

KW - α-Lipoic acid (LA)

KW - Cancer chemoprevention

KW - Dihydrolipoic acid (DHLA)

KW - Inflammation

KW - Oxidative stress

KW - Tumor promotion

UR - http://www.scopus.com/inward/record.url?scp=34247512025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247512025&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2006.12.006

DO - 10.1016/j.bcp.2006.12.006

M3 - Article

C2 - 17403519

AN - SCOPUS:34247512025

VL - 73

SP - 1786

EP - 1795

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 11

ER -